- Home
- SXC vs CRMD Comparison
SXC vs CRMD Comparison
Compare SXC & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXC
- CRMD
- Stock Information
- Founded
- SXC 1960
- CRMD 2006
- Country
- SXC United States
- CRMD United States
- Employees
- SXC N/A
- CRMD N/A
- Industry
- SXC Steel/Iron Ore
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- SXC Industrials
- CRMD Health Care
- Exchange
- SXC Nasdaq
- CRMD Nasdaq
- Market Cap
- SXC 722.8M
- CRMD 753.6M
- IPO Year
- SXC N/A
- CRMD 2010
- Fundamental
- Price
- SXC $9.67
- CRMD $10.15
- Analyst Decision
- SXC Strong Buy
- CRMD Strong Buy
- Analyst Count
- SXC 1
- CRMD 6
- Target Price
- SXC $13.00
- CRMD $15.67
- AVG Volume (30 Days)
- SXC 891.9K
- CRMD 1.5M
- Earning Date
- SXC 01-30-2025
- CRMD 03-11-2025
- Dividend Yield
- SXC 4.96%
- CRMD N/A
- EPS Growth
- SXC 64.98
- CRMD N/A
- EPS
- SXC 1.12
- CRMD N/A
- Revenue
- SXC $1,935,400,000.00
- CRMD $12,262,234.00
- Revenue This Year
- SXC N/A
- CRMD N/A
- Revenue Next Year
- SXC N/A
- CRMD $246.41
- P/E Ratio
- SXC $8.63
- CRMD N/A
- Revenue Growth
- SXC N/A
- CRMD 41184.20
- 52 Week Low
- SXC $7.47
- CRMD $2.89
- 52 Week High
- SXC $12.82
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- SXC 35.00
- CRMD 40.80
- Support Level
- SXC $9.27
- CRMD $11.90
- Resistance Level
- SXC $9.78
- CRMD $12.67
- Average True Range (ATR)
- SXC 0.31
- CRMD 0.73
- MACD
- SXC -0.01
- CRMD -0.27
- Stochastic Oscillator
- SXC 32.00
- CRMD 2.12
About SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.